SCHEMBL19275945

SCHEMBL19275945

C/C=C/C(=O)Nc1cc(C)ccc1OC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 8/20 0.56
▸ KMT2A Q03164 8/20 0.56
▸ MAPT P10636 6/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ GAA P10253 2/20 0.55
▸ CASP3 P42574 1/20 0.55
▸ SENP7 Q9BQF6 1/20 0.55
▸ SENP6 Q9GZR1 1/20 0.55
▸ TP53 P04637 1/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ LTB4R Q15722 1/20 0.54
▸ TSHR P16473 2/20 0.53
▸ CREBBP Q92793 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ POLB P06746 1/20 0.52
▸ HSD17B10 Q99714 1/20 0.52
▸ THRB P10828 1/20 0.50
▸ LMNA P02545 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL862532 0.80 TSHR (0.70) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL11660382 0.80 HPGD (0.70) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL14354684 0.80 GAA (0.74) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL6579496 0.79 SMN1; SMN2 (0.66) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL29451289 0.79 SMN1; SMN2 (0.66) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL13947392 0.78 CREBBP (0.53) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL6464089 0.78 KMT2A (0.61) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL28918511 0.78 SMN1; SMN2 (0.64) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL5534456 0.78 KMT2A (0.66) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL19275929 0.77 TUBB1 (0.60) MEN1KMT2AMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9878977-B2 N-((3,4,5-trimethoxystyryl)aryl)cinnamamide compounds as potential anticancer agents and process for the preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2018-01-30 — — US disclosed
US-20170240503-A1 N-((3,4,5-TRIMETHOXYSTYRYL)ARYL)CINNAMAMIDE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2017-08-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170240503-A1 N-((3,4,5-TRIMETHOXYSTYRYL)ARYL)CINNAMAMIDE COMPOUNDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP51A1, CBR3 MEN1 3274/4885KMT2A 832/4885MAPT 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback